WO2004065403A1 - ヌクレオシド化合物の製造方法 - Google Patents
ヌクレオシド化合物の製造方法 Download PDFInfo
- Publication number
- WO2004065403A1 WO2004065403A1 PCT/JP2004/000048 JP2004000048W WO2004065403A1 WO 2004065403 A1 WO2004065403 A1 WO 2004065403A1 JP 2004000048 W JP2004000048 W JP 2004000048W WO 2004065403 A1 WO2004065403 A1 WO 2004065403A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- formula
- group
- nucleoside compound
- carboxylic acid
- represented
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/16—Purine radicals
- C07H19/167—Purine radicals with ribosyl as the saccharide radical
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/06—Pyrimidine radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/06—Pyrimidine radicals
- C07H19/067—Pyrimidine radicals with ribosyl as the saccharide radical
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/16—Purine radicals
Definitions
- the present invention relates to a method for producing a specific nucleoside compound and a derivative thereof. Further, the present invention provides a method for producing a carboxylic acid nucleoside compound or a salt thereof, more specifically, a method for producing a carboxylic acid nucleoside compound or a salt thereof by oxidizing the nucleoside compound under specific conditions, and under a specific condition. And the like. The present invention relates to a method for crystallizing a carboxylic acid nucleoside compound or a salt thereof by using the method, and producing crystals of the compound or a salt thereof.
- X represents a hydrogen atom, a halogen atom, an amino group, an alkyl group, an aralkyl group, a substituted amino group or a hydroxyl group
- Y represents a hydrogen atom, a halogen atom, an alkyl group, an aralkyl group or an aryl group.
- the nucleoside compound represented by is useful as a synthetic intermediate for pharmaceuticals. Various methods for producing the nucleoside compound are known.
- a sugar compound in which the three hydroxyl groups of the ribose skeleton are protected is subjected to a coupling reaction with a nucleobase, or after protecting the three hydroxyl groups of the nucleoside sugar moiety, is subjected to various reactions.
- a nucleobase By modifying the nucleobase with:
- R 4 has the same meaning as described above, and P 1 P 2 and P 3 are the same or different and each independently represents a hydroxyl protecting group.
- a hydroxyl-protected nucleoside compound represented by the following formula (hereinafter sometimes abbreviated as a protected compound) is obtained and deprotected.
- Method 1 A method in which sodium metal is added three times every hour to the protected compound dissolved in dry methanol in an ice bath and stirred (for example, Journal of Medicinal) Chemistry (Journal of Medicinal Chemistry), (USA), 1985, Vol. 28, No. 11, p. 1642).
- Method 2 A method in which a protected compound is reacted with methanolic ammonia at room temperature (for example, by Bharat K Trivedi et al., “Study's Tow Synthesis Synthesis C2-Substituted Adenosines: Fans”).
- Method 1 has a problem in that a by-product (methoxy 6-position) in which the chlorine atom at the 6-position is substituted with a methoxy group is generated.
- Method 2 ammonia (NH 3 ) reacts at the position of the chlorine atom.
- NH 3 ammonia
- 6-amino body As a result, there was a problem that a by-product (6-amino body) was formed.
- various reports have been made on the deprotection reaction of a protected compound in which the 6-position of the purine ring of the protected compound is an oxo group instead of a chloro group.
- a method using an equivalent or more of a protecting group for example, an acetyl group
- carboxylic acid nucleoside compounds represented by 2 ', 3'-isopropylidene-16-clomouth purine riboside-15, -carboxylic acid represented by the formula are useful compounds as synthetic intermediates for pharmaceuticals, etc. ing.
- a method for producing such a carboxylic acid nucleoside compound for example, a method is known in which the 5'-hydroxyl group of the corresponding nucleoside compound is oxidized to induce a 5'-carboxyl group.
- hypochlorite or hypobromite which is a milder oxidizing agent, and studied.
- hypochlorite or hypobromite is used as the oxidizing agent, the pH value of the reaction solution tends to increase.
- the nucleoside group of the nucleoside compound tends to be hydrolyzed and converted to a hydroxyl group.
- a carboxylic acid nucleoside compound is extracted from a reaction solution into an organic solvent and concentrated to dryness to obtain a solid carboxylic acid nucleoside compound.
- the present inventors have tried to crystallize the nucleoside sulfonic acid compound from such an organic solvent in order to further increase the purification efficiency, but the crystallinity of the compound is poor, such as obtaining an oily target product. It was also found that good results could not be obtained with respect to the purification effect of impurities generated by the above-mentioned hydrolysis. Disclosure of the invention
- An object of the present invention is to provide (1) a method for producing a nucleoside compound in which the generation of by-products is suppressed. Furthermore, an object of the present invention is to provide (2) a method for producing a nucleoside derivative using the method for producing the nucleoside compound.
- Another object of the present invention is to provide (3) a method for producing a carboxylic acid nucleoside compound or a salt thereof by a method suitable for industrial production, that is, by oxidizing the 5′-hydroxyl group of the nucleoside compound, In a process for producing a carboxylic acid nucleoside compound or a salt thereof, which is a one-pot lipoxyl group derivative, a system using hypochlorite or hypobromite, which is highly safe as an oxidizing agent and easy to control the reaction. And a method for efficiently producing a carboxylic acid nucleoside compound by suppressing a hydrolysis reaction which is a side reaction of the oxidation reaction. Further, the object of the present invention is
- An object of the present invention is to provide a method for producing a crystal of a carboxylic acid nucleoside compound, which is capable of efficiently selecting a hydrolyzate generated during an oxidation reaction.
- the present inventors have intensively studied to solve the above problems.
- the expression [I] The molar ratio of the 235'-triacyloxynucleoside compound represented by the formula (1) to the alkali metal hydroxide is 0.01 to 0.
- the present inventors have found that by performing the oxidation reaction of the carboxylic acid nucleoside compound while adjusting the pH value during the oxidation reaction to a specific range, the formation of hydrolyzate is significantly suppressed.
- the present inventors further extract the carboxylic acid nucleoside compound in the reaction solution under an acidic condition into an organic solvent, then back-extract the organic solvent into an alkali aqueous solution, and add an acid to the alkaline aqueous solution. It was found that the neutralization crystallization yielded a highly pure carboxylic acid nucleoside compound crystal in which impurities generated by hydrolysis during the oxidation reaction were remarkably removed.
- the present inventors have completed the present invention based on these findings.
- the present invention includes the following contents.
- R 1 R 2 and R 3 may be the same or different and each independently represents an acyl group, and R 4 is
- X represents a hydrogen atom, a halogen atom, an amino group, an alkyl group, an aralkyl group, a substituted amino group or a hydroxyl group
- Y represents a hydrogen atom, a halogen atom, an alkyl group, an aralkyl group or an aryl group. Shown below).
- 2 3 5'-triacyloxynucleoside compound hereinafter simply referred to as It may be abbreviated as 2 ', 3,, 5'-triacyloxynucleoside compound.
- nucleoside compound [II] A method for producing a nucleoside compound represented by the following formula (hereinafter sometimes simply referred to as nucleoside compound [II]).
- R 4 has the same meaning as the above [1], and R 5 and R 6 may be the same or different, and each independently represents an alkyl group.
- a method for producing a 2,, 3-hydroxyl-protected nucleoside compound represented by the following formula (hereinafter, sometimes abbreviated simply as 2,3′-hydroxyl-protected nucleoside compound).
- R 4 has the same meaning as the above [1], and R 5 and R 6 may be the same or different and each independently represents an alkyl group.
- a method for producing a carboxylic acid compound represented by the following formula (hereinafter sometimes simply referred to as a carboxylic acid compound).
- a nucleoside compound represented by the formula (1) (hereinafter sometimes simply referred to as a nucleoside compound (1)) is referred to as a 2,2,6,6-tetramethylpiperidine-l-oxyl catalyst. And oxidizing it in the presence of hypochlorite or hypobromite while adjusting the pH to the range of 5 to 9, characterized by the formula (2): (Hereinafter, it may be simply referred to as a carboxylic acid nucleoside compound.) Or a method for producing a salt thereof.
- R 9 represents a group represented by the following formula (3) or (4)
- R 7 and R 8 are each independently a hydrogen atom, an acyloxy group, an alkyloxy group, an aralkyloxy group or ier represents a __butyldimethylsilyloxy group, or R 7 and R 8 together represent a group represented by the following formula (5).
- X ′ represents a hydrogen atom, a halogen atom, an amino group, a substituted amino group or a hydroxyl group
- ⁇ ′ represents a hydrogen atom, a halogen atom, an alkyl group or an arylene group.
- R 1 ° and R 11 each independently represent an alkyl group.
- the lipoic acid nucleoside compound represented by the formula (2) in the reaction solution is extracted into an organic solvent under acidic conditions, and then back-extracted from the organic solvent into an alkaline aqueous solution.
- the carboxylic acid nucleoside compound represented by the formula (2) in the reaction solution is extracted into an organic solvent under an acidic condition, and then neutralized by back-extraction from the organic solvent into an aqueous solution.
- the method of the above-mentioned [7], comprising a step of back-extracting into water or neutralizing with an aqueous alkali solution from the organic solvent, and then crystallizing to produce crystals of the salt of the carboxylic acid nucleoside compound.
- the carboxylic acid nucleoside compound represented by the formula (2) is extracted into an organic solvent under acidic conditions, further back-extracted from the organic solvent into an aqueous alkali solution, and an acid is added to the aqueous alkali solution.
- the carboxylic acid nucleoside compound is neutralized and crystallized by a neutralization crystallization method.
- R 9 represents a group represented by the following formula (3) or (4)
- R 7 and R 8 each independently represent a hydrogen atom, an acyloxy group, an alkyloxy group, an aralkyloxy group or A ter ⁇ _butyldimethylsilyloxy group, or R 7 and R 8 together represent a group represented by the following formula (5).
- X ′ represents a hydrogen atom, a halogen atom, an amino group, a substituted amino group or a hydroxyl group
- ⁇ ′ represents a hydrogen atom, a halogen atom, an alkyl group or an alkynole group.
- R 1 G and R 11 each independently represent an alkyl group.
- the carboxylic acid nucleoside compound represented by the formula (2) is 2,3,1'-isopropylidene _ 6-clonal purine liposide 5,1 'carboxylic acid represented by the following formula (6) The method according to any one of [7] to [11].
- I 1 , R 2 and R 3 in the present invention may be the same or different, and each independently represents an acyl group.
- acyl group as used herein means an acyl group having usually 1 to 20 carbon atoms, preferably 2 to 8 carbon atoms, such as acetyl, propioyl, and benzoyl. And acetyl is preferred.
- X represents a hydrogen atom, a halogen atom, an amino group, an alkyl group, an aralkyl group, a substituted amino group or a hydroxyl group
- Y represents a hydrogen atom, a halogen atom, an alkyl group, an aralkyl group or Shows an aryl group.
- the halogen atom is a chlorine atom, a fluorine atom, a bromine atom, or an iodine atom, and among them, a chlorine atom is preferable.
- the alkyl group referred to here is a linear or branched alkyl group, and preferably has 1 to 10 carbon atoms, and more preferably has 1 to 3 carbon atoms.
- methyl, ethyl, propyl and the like can be mentioned, and among them, methyl is preferable.
- the aralkyl group means that the alkyl portion is linear or branched, has a preferred carbon number of 1 to 5, more preferably 1, and an aryl portion has a preferred carbon number of 6 to 10. And more preferably 6 to 8 aralkyl groups.
- Preferred examples include benzyl and the like.
- the aryl group is an aryl group having a preferred carbon number of 6 to 10, more preferably 6 to 8.
- Preferred examples include a ferul group.
- the substituted amino group is an amino group mono- or di-substituted by the following substituents.
- the di-substituted amino groups may have the same or different substituents.
- the substituent include an acyl group (having the same meaning as described above, preferably having 1 to 7 carbon atoms, such as acetyl, propioel, and benzoyl, and particularly preferably acetyl), and an alkyl group (as defined above). And particularly preferably methyl and ethyl), aryl groups (defined as above, particularly preferably phenyl), and aralkyl groups (defined as above, particularly preferably benzyl).
- substituted amino group examples include acetylamino, methylamino, ethylamino, phenylamino, benzylamino and the like, among which acetylamino and benzylamino are preferable.
- R 5 and R 6 in the present invention may be the same or different and each independently represents an alkyl group.
- the alkyl group here is the same as the alkyl group for X and Y.
- the method for producing the nucleoside compound [II] according to the present invention comprises: 2, 3, 3 ', 5'-triacyloxy nucleoside compound; It is characterized by being subjected to deacylation using 0.01 to 0.5 times the amount of the triacyloxynucleoside compound. Specifically, for example, in a solvent, a 2 ′, 3 ′, 5′-triacyloxynucleoside compound and an alkali metal hydroxide (2,3,5′-triacyloxynucleoside compound of 0. (0.1-0.5 times mol) is added and stirred.
- Examples of the solvent used for producing the nucleoside compound [II] include a methanol-containing solvent (eg, methanol or a mixed solvent of methanol and an organic solvent).
- a methanol-containing solvent eg, methanol or a mixed solvent of methanol and an organic solvent.
- the solvent other than methanol is not particularly limited as long as it is an organic solvent, and examples thereof include tetrahydrofuran and acetonitrile.
- a single solvent of methanol is particularly preferable.
- the total amount of the solvent used is usually 2 to 20, preferably 5 to 15, based on 2 ', 3,5'-triacyloxynucleoside compound 1 by weight.
- alkali metal hydroxide examples include, for example, sodium hydroxide, potassium hydroxide, lithium hydroxide and the like, and among them, sodium hydroxide is preferable. It is essential in the present invention that the amount of the alkali metal hydroxide used is, in molar ratio, ⁇ .01 to 0.5 times the 2 ′, 3 ′, 5′-triacyloxynucleoside compound. If the amount of metal hydroxide used exceeds this range, the generation of by-products (6-position methoxy form when the nucleobase is purine base, 4-position methoxy form when the pyrimidine base is pyrimidine base) increases, If the amount decreases, the reaction will not be completed. The preferred amount is from 0.03 to 0,3,2,3 ', 5, -triacyloxynucleoside compound in a molar ratio. 4 times.
- the temperature for the production of the nucleoside compound [II] is usually from 20 to 50 ° C, preferably from 0 to 20 ° C.
- the nucleoside compound [II] can be isolated and purified by a conventional method. For example, after the reaction is completed, an acid (eg, acetic acid, etc.) and an organic solvent (eg, ethyl acetate, etc.) are added and stirred, and the precipitate is collected by filtration and dried to obtain a nucleoside compound [II ] Can be obtained.
- an acid eg, acetic acid, etc.
- an organic solvent eg, ethyl acetate, etc.
- the 2 ', 3'-hydroxyl-protected nucleoside compound of the present invention can be easily produced from the nucleoside compound [II] of the present invention according to a method known to those skilled in the art.
- the 2 ', 3,1-hydroxyl-protected nucleoside compound includes the following formula (V):
- the isopropylidene compound represented by is particularly preferable.
- the nucleoside compound [II] obtained by the method of the present invention can be converted to the isopropylidene compound of the formula [V] by a conventional method, for example, (A) an acid catalyst in a non-protonic organic solvent.
- the nucleoside compound [II] is reacted with 2,2-dimethoxypropane in the presence of acetic acid, or acetone is used as a solvent and a reaction reagent in the presence of an acid catalyst (B). Can be carried out.
- Examples of the acid catalyst used in the methods (A) and (B) include inorganic acids such as hydrochloric acid and sulfuric acid, and organic acids such as methanesulfonic acid and toluenesulfonic acid (including hydrates thereof). Is mentioned.
- the amount of the acid catalyst to be used is usually 0.01 to 1 times, preferably 0.01 to 0.5 times by mole ratio to the nucleoside compound [II]. It is twice.
- Examples of the nonprotonic organic solvent used in the above method (A) include acetone, acetetril, tetrahydrofuran, dichloromethane, and the like.
- the amount of the solvent used is expressed in terms of the weight ratio of the nucleoside compound [II] 1. On the other hand, it is usually 5 to 50, preferably 8 to 20. '
- the amount of 2,2-dimethoxypropane used in the above method (A) is usually 1 to 5, preferably 1 to 3, relative to 1 of the nucleoside compound [II].
- the amount of acetone used in the above method (B) is usually 5 to 50, and preferably 8 to 20 by weight based on 1 nucleoside compound [II].
- the conversion of the nucleoside compound [II] to the isopropylidene compound is carried out at a reaction temperature of usually 0 ° C to 50 ° C, preferably 0 ° C to room temperature, and the reaction is usually carried out at 0 ° C. Ends in 5 to 24 hours, preferably 1 to 5 hours.
- 2,3-Hydroxyl-protected nucleoside compounds other than the isopropylidene compound can also be produced by the same method as that for producing the isopropylidene compound or a method analogous thereto.
- Isolation and purification of the 2 ', 3'-hydroxyl-protected nucleoside compound may be performed by a conventional method.
- an alkali for example, sodium hydrogen carbonate
- the solution is concentrated under reduced pressure to precipitate.
- the material is filtered, washed with water and dried.
- the carboxylic acid compound according to the present invention is a nucleoside compound according to the present invention.
- the isopropylidene carboxylic acid compound represented by the formula is particularly preferable.
- Conversion of the 2 ', 3'-hydroxyl-protected nucleoside compound to a carboxylic acid compound can be performed by oxidizing the 2,3'-hydroxyl-protected nucleoside compound.
- Examples of such a method include a conventionally known method, for example, a method disclosed in JP-A-2000-524801, Tetrahedron Letters, vol. 37, No. 10, 15, 567-157. And methods based on them.
- -As a method capable of producing a carboxylic acid compound having a higher purity than these conventionally known methods
- 2 ', 3, -hydroxyl-protected nucleoside compound can be prepared by using 2,2,6,6-tetramethylpiperidine-1-1.
- TEMPO catalyst hydroxy catalyst
- hypochlorite or hypobromite while adjusting
- reaction solvent that can be used in performing the above reaction, it is preferable to use a mixed solvent of water and an organic solvent, or a two-layer solvent in which an aqueous layer and an organic solvent layer are separated.
- the organic solvent may be any solvent that is not affected by the oxidation reaction.For example, when used as a mixed solvent with water, acetotrile, tetrahydrofuran, acetone, etc. Examples thereof include form, dichloromethane, tert-methyl methyl ether, and ethyl acetate.
- the amount of the reaction solvent to be used is generally 3 to 50, preferably 5 to 20, with respect to 2 ', 3,1-hydroxyl-protected nucleoside compound 1 by weight. When a mixed solvent of water and an organic solvent or a two-layer solvent is used as the reaction solvent, it is sufficient that the total amount of the solvent is included in this range.
- TEMPO catalyst other than TEMPO, oxidation catalyst similar to TEMPO TEMPO-like compounds that exert their functions.
- TEMPO-like compounds include 4-hydroxy-1,2,2,6,6-tetramethylpiperidine_1-oxy, 4-methoxy-2,2,6,6-tetramethylpiperidine_1-oxy, -Hydroxy-1,2,2,6,6-tetramethylpiperidine-11-oxybenzoate.
- the amount of the TEMPO catalyst used is usually from 0.001 to 0.3, preferably from 0. 05 to 0.02, based on the molar ratio of 2 ', 3, -hydroxyl protected nucleoside compound 1. It is.
- hypochlorite examples include sodium hypochlorite, calcium hypochlorite, and the like.
- hypobromite examples include sodium hypobromite.
- Sodium hypochlorite and sodium hypobromite are usually marketed in the form of aqueous solutions, and calcium hypochlorite is usually marketed in solid form.
- the amount of hypochlorite or hypobromite used is usually 1.9 to 3.0, preferably 2., relative to 2 ', 3'-hydroxyl protected nucleoside compound 1 in a molar ratio.
- the ⁇ H at the time of performing the oxidation reaction is adjusted to the range of 5 to 9, preferably 6.5 to 8.
- the pH increases, the 2 ', 3'-hydroxyl-protected nucleoside compound tends to decompose, and when the pH is too low, the reaction rate of the oxidation reaction tends to decrease.
- the oxidation reaction can be performed, for example, by adding hypochlorite or hypobromite to a solvent in which a 2 ′, 3′-hydroxyl protected nucleoside compound and a TEMPO catalyst are present. It is not necessary that the 3'-hydroxyl-protected nucleoside compound be completely dissolved in the solvent, and if the target carboxylic acid compound is dissolved in the solvent, the reaction is carried out in a suspended state. You may.
- the hypochlorite or hypobromite is preferably added as an aqueous solution. For example, a commercially available solid such as calcium hypochlorite can be added as it is. When hypochlorite or hypobromite is added, pH tends to increase.
- hydrolyzed p H value of the reaction solution with the addition becomes too high between the p H 5 to 9, preferably 6. While adjusting to a range of 5-8, is to gradually added portionwise preferable.
- the addition can be carried out usually for 30 minutes to 5 hours, preferably for 2 to 4 hours.
- the reaction may be carried out by dissolving a buffer such as sodium bicarbonate, potassium bicarbonate, or sodium hydrogen phosphate in the reaction solution so that the pH can be easily adjusted.
- a buffer may be dissolved in the reaction solution from the beginning.However, depending on the buffer, the pH value tends to increase in the initial stage of the reaction. , PH should be adjusted within the above-mentioned optimum range as much as possible to suppress the progress of the hydrolysis reaction as much as possible.
- the formation of the target carboxylic acid compound acts to lower the pH of the reaction solution, even if the H value in the initial stage of the reaction is slightly high, the formation of hypochlorite or hypobromite may occur. Optimum in a relatively short time by dividing the addition into small portions! It is possible to adjust within H.
- the pH is adjusted by adjusting the addition rate of hypochlorite or hypobromite and adjusting the buffer as described above, as well as by adding sodium hydroxide, sodium carbonate,
- the reaction can be carried out by appropriately adding a base such as a salt, or an acid such as phosphoric acid, hydrochloric acid or sulfuric acid.
- oxidation is performed while adjusting the pH, it is difficult to completely prevent the hydrolysis reaction.
- the crystallization method of the present invention described below by obtaining the target crystal, impurities generated by hydrolysis can be efficiently removed.
- the oxidizing agent (a compound having an oxidizing ability derived from the added hypochlorite or hypobromite) remaining in the reaction solution is added to a bisulfite such as sodium bisulfite.
- a bisulfite such as sodium bisulfite.
- Decomposition is preferred.
- the bisulfite may be added in the form of a solid or an aqueous solution.
- the amount of addition is not particularly limited, and the progress of decomposition of the oxidizing agent is checked using a peroxide test paper (for example, Merckoquant: trade name of Merck Co., Ltd.).
- the 2,3,5'-triacyloxynucleoside compound used as a raw material can be produced, for example, by the method described in Nucleic Acid Chem. (1991), 264-268.
- one of the raw materials, 2 ', 3', 5'-triacetyl-6-chloropurine liposide is obtained by adding thionyl chloride dropwise to 2 ', 3,5,1-triacetylinosine in a solvent and refluxing. After stirring, it can be produced by post-treatment in a conventional manner.
- the carboxylic acid compound of the present invention can be used as a compound such as adenosine A1 agonist, which is useful as a pharmaceutical, according to or according to the method described in, for example, JP-A-2000-514801. Can be guided to.
- the above oxidation reaction oxidizes only the 5′-position, it is preferable that the hydroxy groups at the 2,2- and 3′-positions of the report portion of the nucleoside compound are protected.
- the sulfonic acid nucleoside compound represented by the formula (2) can be efficiently converted. It can be produced, and the hydrolysis reaction that can occur during the oxidation reaction can be suppressed.
- R 9 represents a group represented by the following formula (3) or (4).
- nucleoside compound represented by the formula (1) represents any one of the following compounds represented by the following (l_a) or (1-1b), and the carboxylic acid nucleoside represented by the formula (2)
- the compound represents any of the compounds represented by the following (2-a) or (2-b).
- X ′ is a hydrogen atom, a halogen atom, an amino group, a substituted (that is, protected) amino Represents a hydroxyl group or a hydroxyl group.
- Examples of the halogen atom include a chlorine atom, a bromine atom, and a fluorine atom.
- Examples of the substituted (that is, protected) amino group include, for example, an acylamino group having 1 to 7 carbon atoms (eg, an acetylamino group, a benzoylamino group, etc.) and an alkylamino group having 1 to 6 carbon atoms (eg, a methylamino group, etc.) ), An aralkylamino group having 7 to 11 carbon atoms (for example, a benzylamino group) and the like.
- Y ′ represents a hydrogen atom, a halogen atom, an alkyl group or an aralkyl group.
- the halogen atom include a chlorine atom, a bromine atom, and a fluorine atom.
- alkyl group examples include an alkyl group having 1 to 6 carbon atoms such as a methyl group.
- aralkyl group examples include an aralkyl group having 7 to 11 carbon atoms such as a benzyl group.
- R 7 and R 8 each independently represent a hydrogen atom, an acyloxy group, an alkyloxy group, an aralkyloxy group, or a tert-butyldimethylsilyloxy group, or R 7 and R 8 And together represent a group represented by the following formula (5).
- ⁇ ⁇ ⁇ ! ⁇ 1 ⁇ each independently represents an alkyl group.
- the alkyl group include an alkyl group having 1 to 6 carbon atoms such as a methyl group.
- acyloxy group examples include an acetyl group having 1 to 7 carbon atoms such as an acetyloxy group and a benzoyloxy group.
- alkyloxy group examples include an alkyloxy group having 1 to 6 carbon atoms such as a methyloxy group.
- aralkyloxy group examples include an aralkyloxy group having 7 to 11 carbon atoms, such as a benzyloxy group.
- the alkyl group represented by R 1 0 or R 1 for example, an alkyl group of from 1 to 6 carbon such as a methyl group.
- Nucleoside compound represented by formula (1) in the present invention for example, journal Honoré O Bed Organic ChemStation tree (Journal of Organic Chemistry; N 1 9 8 7 years, 5 2 Certificates, 1 3 4 4-1 3 4 7
- a nucleoside compound represented by the formula (1) is converted to a 2,2,6,6-tetramethylpiperidine-111-oxycatalyst (TEMPO catalyst), and hypochlorite or hypobromite.
- TEMPO catalyst 2,2,6,6-tetramethylpiperidine-111-oxycatalyst
- hypochlorite or hypobromite By oxidizing (TEMPO-catalyzed oxidation) while adjusting the pH to a range of 5 to 9 in the presence of the compound, a sulfonic acid nucleoside compound represented by the formula (2) or a salt thereof can be obtained.
- a reaction solvent it is preferable to use a mixed solvent of water and an organic solvent, or a two-layer solvent in which an aqueous layer and an organic solvent layer are separated.
- Any organic solvent may be used as long as it is not affected by the oxidation reaction.
- an organic solvent such as acetate nitrile, tetrahydrofuran, acetone, or a two-layer solvent is used.
- examples thereof include organic solvents such as chloroform, dichloromethane, ⁇ er ⁇ ⁇ ⁇ _butyl methyl ether, and acetates (eg, methyl acetate, ethyl acetate, etc.).
- the amount of the reaction solvent to be used is generally 3 to 50, preferably 5 to 20, by weight based on 1 of the nucleoside compound (1).
- the above-mentioned mixed solvent of water and an organic solvent or a two-layer solvent it is sufficient that the entire solvent is included in this range.
- TEMPO catalyst includes the same oxidation as 2,2,6,6-tetramethylpiperidine-l-loxy (TEMPO) and TEMPO A similar compound of TEMPO, which exerts a catalytic function. Similar compounds of TEMPO include, for example, 4-hydroxy
- the amount of the TEMPO catalyst used can be 6-tetramethinolebiperidine-11-oxybenzoate, etc.
- the molar ratio of the nucleoside compound (1) to the nucleoside compound (1) is usually from 0.001 to 0.3. And preferably 0.005 to 0.02.
- Examples of hypochlorite include sodium hypochlorite, calcium hypochlorite, and the like.
- Examples of the hypobromite include sodium hypobromite.
- Sodium hypochlorite and sodium hypobromite are usually marketed in the form of aqueous solutions. Hypochlorite is usually sold in solid form.
- the amount of hypochlorite or hypobromite used is the molar ratio of nucleoside compound
- the ratio is usually 1.9 to 3.0, preferably 2.0 to 2.5, more preferably 2.0 to 2.3. If the amount is too small, the reaction becomes insufficient and the raw materials tend to remain as impurities. If the amount used is too large, it is economically unfavorable and hydrolytic impurities tend to increase.
- the pH at the time of performing the oxidation reaction is adjusted to the range of 5 to 9, preferably 6.5 to 8.
- the nucleoside compound (1) tends to decompose, and when the pH is too low, the reaction rate of the oxidation reaction tends to decrease.
- the oxidation reaction can be performed, for example, by adding hypochlorite or hypobromite to a solvent in which the nucleoside compound (1) and the TEMPO catalyst are present. It is not necessary that the nucleoside compound (1) is completely dissolved in the solvent, and the reaction may be carried out in a suspended state as long as the target nucleoside compound can be dissolved in the solvent. .
- the hypochlorite or hypobromite is preferably added as an aqueous solution. For example, a commercially available solid such as calcium hypochlorite can be added as it is.
- the pH tends to increase when hypochlorite or hypobromite is added, and when added in a short period of time, the pH value of the reaction solution becomes too high and hydrolysis proceeds.
- the reaction may be carried out by dissolving a buffer such as sodium hydrogen carbonate, potassium hydrogen carbonate, sodium hydrogen phosphate or the like in the reaction solution so that the pH can be easily adjusted.
- a buffer such as sodium hydrogen carbonate, potassium hydrogen carbonate, sodium hydrogen phosphate or the like
- Such a buffer may be dissolved in the reaction solution from the beginning.However, depending on the buffer, the pH tends to increase in the initial stage of the reaction. It is preferable to adjust as much as possible within the above-mentioned optimum range and to suppress the progress of the hydrolysis reaction as much as possible.
- the formation of the target carboxylic acid nucleoside compound acts to lower the pH of the reaction solution, even when the pH value in the initial stage of the reaction is slightly high, addition of hypochlorite or hypobromite is not necessary. It is possible to adjust the pH to an optimum pH in a relatively short time by adding small portions. pH adjustment, as described above In addition to adjusting the rate of addition of hypochlorite or hypobromite and adjusting the buffering agent, bases such as sodium hydroxide, sodium carbonate, and hydroxide hydration, and acids such as phosphoric acid, hydrochloric acid, and sulfuric acid are used. It can also be performed by appropriately adding. It is difficult to completely prevent the hydrolysis reaction even when the oxidation is performed while adjusting the pH. However, by obtaining the target crystal in accordance with the crystallization method ′ of the present invention described below, impurities generated by hydrolysis during oxidation can be efficiently removed.
- the oxidizing agent (a compound having an oxidizing ability derived from added hypochlorite or hypobromite) remaining in the reaction solution and a bisulfite such as sodium bisulfite are added. It is preferable to decompose.
- the oxidizing agent is mixed in the target substance, there is a possibility that a problem such as adversely affecting the reaction may occur when the derivative compound is further produced using the target substance.
- the bisulfite may be added in the form of a solid or in the form of an aqueous solution.
- the amount of addition is not particularly limited, and the progress of the decomposition of the oxidizing agent is confirmed with a peroxide test paper (for example, Merckoquant (trade name of Merck)), and all the oxidizing agents are decomposed. It is preferable to add up to. It is not preferable to use sulfites such as sodium sulfite since they show a basic property and tend to cause a hydrolysis reaction.
- the extract is back-extracted from the organic solvent into an aqueous alkaline solution, and an acid is added to the obtained aqueous alkali solution to add the carboxylic acid.
- an acid is added to the obtained aqueous alkali solution to add the carboxylic acid.
- the target carboxylic acid nucleoside compound after extracting the target carboxylic acid nucleoside compound into an organic solvent under acidic conditions, Neutralization by back-extraction into a solution or back-extraction from the organic solvent into water and neutralization with an aqueous solution of sodium hydroxide, followed by crystallization, crystallize the crystals of the salt of the nucleoside compound. It is also possible to get.
- the salt of the carboxylic acid nucleoside compound include alkali metal salts such as sodium salt and potassium salt.
- the chlororiboside compound which is present in the reaction solution, is extracted into an organic solvent under acidic conditions.
- An acid such as phosphoric acid, hydrochloric acid, sulfuric acid or the like is added to the reaction solution, and the mixture is acidified by adjusting H to a range of 1.5 to 3.5, preferably 2,0 to 3.0.
- an acid is added to the aqueous layer to adjust the pH to the above range.
- the organic solvent used for the extraction include ethyl acetate, black form, tert-butyl methyl ether, and the like, with ethyl acetate being particularly preferred.
- an organic solvent having high water solubility is used for the reaction solution
- the organic solvent may be added after or before the adjustment of ⁇ ⁇ .
- an extraction operation is performed according to a conventional method, and the organic layer from which the target substance has been extracted is separated.
- the temperature at the time of extraction is not particularly limited, but it can be usually in the range of 10 to 40 ° C.
- the amount of the organic solvent used in the extraction is usually 5 to 50, preferably 8 to 20 with respect to the target substance 1 in a weight ratio. Extraction may be performed multiple times as necessary.
- the target substance is back-extracted into an aqueous alkaline solution from the organic solvent from which the target substance has been extracted.
- a base such as sodium hydroxide, potassium hydroxide, sodium hydrogen carbonate or the like is added to water, and the pH is adjusted to 5 to 12, preferably 6 to 8, to obtain an alkaline aqueous solution.
- An extraction operation is carried out according to a conventional method using the above organic solvent and the aqueous alkali solution, and the target substance is back-extracted into a water layer (alkali aqueous solution layer), and then the aqueous layer from which the target substance is extracted is separated.
- the temperature at the time of extraction is not particularly limited, but can be usually in the range of 0 to 40 ° C.
- the amount of water used for extraction is 5 to 50, preferably 8 to
- the extraction may be performed a plurality of times as necessary.
- Neutralization crystallization may be performed by appropriately adding an organic solvent miscible with water, such as methanol, ethanol, or acetone, to the alkaline aqueous solution.
- the amount of the organic solvent to be added can be usually in the range of 1 to 50 with respect to 1 of the alkaline aqueous solution in volume ratio.
- the acid used for the neutralization crystallization include phosphoric acid, hydrochloric acid, and sulfuric acid.
- the pH at which the neutralization crystallization is performed can be generally 1.5 to 3.5, preferably 2.0 to 3.0.
- the crystallization temperature can be generally 0 to 80 ° C S, preferably 10 to 40 ° C.
- the crystallization is usually performed with stirring.
- the slurry obtained by the crystallization can be separated into solid and liquid by a conventional method such as filtration or centrifugation to isolate the crystals. If necessary, the crystals may be washed with water, alcohol or the like, and a drying step may be introduced according to a conventional method. In this way, the obtained crystals become high-purity crystals, and the hydrolyzate that is difficult to select by the method of the present invention can be efficiently removed.
- 2,3,5,5 Triacetyl inosine (20 g) was added to chloroform (160 ml) and N, N-dimethylformamide (2.7 g), and thionyl chloride (19.9 g) was added dropwise. Then, the mixture was stirred under reflux for 3 hours. Water (200 ml) was added while cooling in an ice bath, and the mixture was stirred for 1 hour, and then separated. After washing with 5 ° / 0 aqueous sodium bicarbonate solution and saturated saline solution, drying over sodium sulfate and concentration to dryness, 2 ′, 3 ′, 5′-triacetyl-6-clomouth purine liposide (24.4 g) was obtained. Obtained as an oil.
- 2,3,5,1-Triacetyl-6-clorin purine riboside (oil, 6.0 g) was dissolved in methanol (30 ml), cooled to 5 ° C, and 1N sodium hydroxide-methanol solution (0.6 ml) was added. Was added and stirred for 5 hours.
- Acetic acid (0.04 ml) and ethyl acetate (30 ml) were added to the reaction solution, and the mixture was stirred under ice cooling for 1 hour. The precipitate was collected by filtration, washed with ethyl acetate, and dried at 40 ° C. under reduced pressure to give the title compound (3.08 g).
- ethyl acetate 4880 ml was added to the reaction solution, the aqueous layer was adjusted to pH 2.8 with 6N hydrochloric acid, and extracted at 25 ° C.
- ethyl acetate (1120 ml) was added to the remaining aqueous layer, and the extraction operation was performed again.
- the organic solvent layer was separated, combined with the previously obtained organic solvent layer, water (5064 ml) was added to the organic solvent layer, and the aqueous layer was adjusted to pH 6.7 with an aqueous sodium hydroxide solution.
- the reverse extraction operation was performed at 25 ° C.
- the aqueous layer from which the target product was extracted was separated, and the aqueous layer was adjusted to pH 2.8 by adding 6 N hydrochloric acid, and neutralized and crystallized at 30 ° C. After performing a crystallization operation with stirring for about 17 hours, the slurry was filtered, and the separated crystals were washed with water and reduced at 50 ° C under reduced pressure. (4) The crystals were dried to obtain crystals of 2,3,1-isopropylidene-6-clopurine riboribosid-5, monobasic rubonic acid (493 g, 1.45 mol).
- ethyl acetate 4880 ml was added to the reaction solution, the pH of the aqueous layer was adjusted to 2.8 with 6N hydrochloric acid, and extraction was performed at 25 ° C.
- 120 ml of ethyl acetate was added to the remaining aqueous layer, and the extraction operation was performed again.
- water 5064 ml was added to the organic solvent layer, and the aqueous layer was adjusted to pH 6.7 with an aqueous sodium hydroxide solution. Thereafter, a reverse extraction operation was performed at 25 ° C.
- the aqueous layer from which the desired product was extracted was separated, the aqueous layer was adjusted to pH 2.8 by adding 6N hydrochloric acid, and neutralized and crystallized at 30 ° C. After performing the crystallization operation with stirring for about 17 hours, the slurry was filtered, and the separated crystals were washed with water, dried under reduced pressure at 50 ° C overnight, and dried at 2 ', 3,1-isopropylidene. Crystals of 1-6-chloropurine riboside-15′-capillonic acid were obtained in 493 g (1.45 mo 1). The content of impurities in the crystals was confirmed by HP LC and found to be 0.1%.
- Example 6 2 , 3'-Isopropylidene-16-chloropurine liposide 5, 2,3-Rubonic acid 2,, 3'I-isopropylidene-6-chloropurine riboside 0.6 g (1.8 mmo1) of acetonitrile ( 3.5 ml) and water (3 ml), and sodium hydrogencarbonate (0.2 g) and tetramethylpyridyloxy (TEMPO) (8 mg, 0.05 mmo 1) were added. . While stirring at 5 ° C., 60 ° / o calcium hypochlorite (0.57 g, 4.39 mmo 1) was divided into four portions over 1 hour, and the mixture was stirred for 1 hour. The pH immediately after the start of the reaction was 9.5, and was adjusted to pH 7 to 8 about 10 minutes after the addition of calcium hypochlorite, and the pH was maintained thereafter.
- acetonitrile 3.5 ml
- water 3 ml
- sodium hydrogencarbonate 0.2 g
- the nucleoside compound [II] it is possible to produce the nucleoside compound [II] while suppressing the generation of by-products. Therefore, the nucleoside compound [II] can be used to produce a nucleoside derivative (2,3′-hydroxyl protected nucleoside compound [111], carboxylic acid compound [IV]).
- a nucleoside compound of the formula (2) or a salt thereof can be produced by a method suitable for industrial production. That is, according to the present invention, the 5′-hydroxyl group of the nucleoside compound represented by the formula (1) is oxidized to form a carboxylate represented by the formula (2), which is a 5′-hydroxyl group derivative.
- hypochlorite or hypobromite which is highly safe as an oxidizing agent and easy to control the reaction, can be used. The reaction can be significantly suppressed.
- the resulting hydrolyzate can be efficiently selected, and a highly pure carboxylate nucleoside compound represented by the formula (2) or a salt thereof is produced by a method suitable for industrial production. be able to.
- This application is based on patent applications No. 2003-01 / 0373, No. 2003-122614, and No. 2003-169495 filed in Japan, the contents of which are incorporated by reference herein. is there.
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Saccharide Compounds (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Description
Claims
Priority Applications (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP04700532A EP1589027A1 (en) | 2003-01-17 | 2004-01-07 | Processes for production of nucleosides |
CA002513545A CA2513545A1 (en) | 2003-01-17 | 2004-01-07 | Processes for production of nucleosides |
JP2005508024A JPWO2004065403A1 (ja) | 2003-01-17 | 2004-01-07 | ヌクレオシド化合物の製造方法 |
US11/181,985 US20060014944A1 (en) | 2003-01-17 | 2005-07-15 | Processes for production of nucleosides |
Applications Claiming Priority (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2003010373 | 2003-01-17 | ||
JP2003-10373 | 2003-01-17 | ||
JP2003-122614 | 2003-04-25 | ||
JP2003122614 | 2003-04-25 | ||
JP2003169534 | 2003-06-13 | ||
JP2003-169534 | 2003-06-13 |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US11/181,985 Continuation US20060014944A1 (en) | 2003-01-17 | 2005-07-15 | Processes for production of nucleosides |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2004065403A1 true WO2004065403A1 (ja) | 2004-08-05 |
Family
ID=32776802
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2004/000048 WO2004065403A1 (ja) | 2003-01-17 | 2004-01-07 | ヌクレオシド化合物の製造方法 |
Country Status (5)
Country | Link |
---|---|
US (1) | US20060014944A1 (ja) |
EP (1) | EP1589027A1 (ja) |
JP (1) | JPWO2004065403A1 (ja) |
CA (1) | CA2513545A1 (ja) |
WO (1) | WO2004065403A1 (ja) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1695967A1 (en) * | 2003-11-04 | 2006-08-30 | Ajinomoto Co., Inc. | Processes for production of pyrimidine derivatives and intermediates |
US7596078B2 (en) | 2005-11-10 | 2009-09-29 | Acellent Technologies, Inc. | Method and apparatus for reducing crosstalk in a structural health monitoring system |
ES2641190T3 (es) * | 2007-03-14 | 2017-11-08 | Can-Fite Biopharma Ltd. | Procedimiento de síntesis de IB-MECA |
CN105085595B (zh) * | 2015-09-15 | 2017-12-29 | 安阳工学院 | 一种脱酰基保护合成2,6‑位卤代嘌呤核苷的方法 |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH01272595A (ja) * | 1988-04-25 | 1989-10-31 | Central Glass Co Ltd | 2’―デオキシ―5―フルオロウリジン―ジアシル誘導体の製造方法 |
JPH05508864A (ja) * | 1990-09-25 | 1993-12-09 | ローヌ−プーラン ローラー インターナショナル (ホウルディングス) インコーポレイテッド | 抗昇圧および抗虚血特性を有する化合物 |
JPH07300492A (ja) * | 1992-12-18 | 1995-11-14 | F Hoffmann La Roche Ag | ▲n4▼−アシル−5’−デオキシ−5−フルオロシチジン誘導体の新規製造法 |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB2218417B (en) * | 1988-04-21 | 1991-09-18 | Central Glass Co Ltd | Preparation of 2'-deoxy-5,6-dihydro-5-fluoro-6-hydroxy uridine and diaryl 2'- deoxy-5-fluorouridines |
EP1553090A4 (en) * | 2002-06-14 | 2006-07-05 | Ajinomoto Kk | PROCESS FOR PREPARING A PYRIMIDINE COMPOUND |
JP2004323433A (ja) * | 2003-04-25 | 2004-11-18 | Ajinomoto Co Inc | 5’−アシルオキシヌクレオシド化合物の製造方法 |
EP1529778A1 (en) * | 2003-11-04 | 2005-05-11 | Ajinomoto Co., Inc. | Production method of pyrimidine derivative, intermediate therefor |
EP1533306A1 (en) * | 2003-11-04 | 2005-05-25 | Ajinomoto Co., Inc. | Azlactone compound and method for preparation thereof |
JP4613501B2 (ja) * | 2004-03-17 | 2011-01-19 | 味の素株式会社 | 5−保護アミノピリミジン化合物の製造方法 |
JP4501015B2 (ja) * | 2004-03-17 | 2010-07-14 | 味の素株式会社 | アミノピリミジン化合物の製造方法 |
-
2004
- 2004-01-07 EP EP04700532A patent/EP1589027A1/en not_active Withdrawn
- 2004-01-07 CA CA002513545A patent/CA2513545A1/en not_active Abandoned
- 2004-01-07 JP JP2005508024A patent/JPWO2004065403A1/ja not_active Abandoned
- 2004-01-07 WO PCT/JP2004/000048 patent/WO2004065403A1/ja not_active Application Discontinuation
-
2005
- 2005-07-15 US US11/181,985 patent/US20060014944A1/en not_active Abandoned
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH01272595A (ja) * | 1988-04-25 | 1989-10-31 | Central Glass Co Ltd | 2’―デオキシ―5―フルオロウリジン―ジアシル誘導体の製造方法 |
JPH05508864A (ja) * | 1990-09-25 | 1993-12-09 | ローヌ−プーラン ローラー インターナショナル (ホウルディングス) インコーポレイテッド | 抗昇圧および抗虚血特性を有する化合物 |
JPH07300492A (ja) * | 1992-12-18 | 1995-11-14 | F Hoffmann La Roche Ag | ▲n4▼−アシル−5’−デオキシ−5−フルオロシチジン誘導体の新規製造法 |
Non-Patent Citations (1)
Title |
---|
KUSACHI S. ET AL: "Dog coronary artery adenosine receptor: Structure of the N6-alkyl subregion", JOURNAL OF MEDICINAL CHEMISTRY, vol. 28, no. 11, 1985, pages 1636 - 1643, XP000566463 * |
Also Published As
Publication number | Publication date |
---|---|
EP1589027A1 (en) | 2005-10-26 |
CA2513545A1 (en) | 2004-08-05 |
JPWO2004065403A1 (ja) | 2006-05-18 |
US20060014944A1 (en) | 2006-01-19 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US8193354B2 (en) | Process for preparation of Gemcitabine hydrochloride | |
JP3653292B2 (ja) | 5−メチルウリジンを用いる2’,3’−ジデヒドロ−3’−デオキシチミジン(d4T)の大量製造法 | |
WO2008069440A1 (en) | The preparation method of 2-de0xy-l-rib0se | |
JP3042073B2 (ja) | ヌクレオシド誘導体とその製造方法 | |
US20060014944A1 (en) | Processes for production of nucleosides | |
JPH0859662A (ja) | N−9置換グアニン化合物の調製 | |
JP2008266172A (ja) | 3−o−アルキル−5,6−o−(1−メチルエチリデン)−l−アスコルビン酸の製造方法および5,6−o−(1−メチルエチリデン)−l−アスコルビン酸の製造方法 | |
JPH0797391A (ja) | ヌクレオシド誘導体とその製造方法 | |
JP4691101B2 (ja) | 1−α−ハロ−2,2−ジフルオロ−2−デオキシ−D−リボフラノース誘導体及びその製造方法 | |
KR100908363B1 (ko) | 트라이-O-아세틸-5-데옥시-β-D-라이보퓨라노즈의입체선택적 제조방법 및 이의 분리방법 | |
EP0653437B1 (en) | Process for preparing AZT and derivatives thereof | |
US7361745B2 (en) | Process for the preparation of 1-chloro-3,5-di-o-acyl-2-deoxy-l-ribofuranoside derivatives | |
EP0984976B1 (en) | Process for the preparation of a deoxyuridine derivative | |
CA2574954C (en) | 1-.alpha.-halo-2,2-difluoro-2-deoxy-d-ribofuranose derivatives and process for the preparation thereof | |
JP2005239552A (ja) | 2’−デオキシ−5−トリフルオロメチルウリジンの製造方法 | |
CN108101881B (zh) | 用于制备曲贝替定的方法及其中间体 | |
JP2007137843A (ja) | リボフラノース化合物およびプリンヌクレオシド化合物の製造方法 | |
US20100267940A1 (en) | Method for Producing 4-Deoxy-4-Fluoro-D-Glucose Derivative | |
JPH0899990A (ja) | アジド化ヌクレオシド誘導体の製造方法 | |
WO1997006179A1 (fr) | Procede permettant de produire des derives d'azidonucleoside | |
JPWO2010079813A1 (ja) | イノシン誘導体の製造方法 | |
CN109912673A (zh) | 坎格雷洛中间体及其制备方法 | |
JP2002338593A (ja) | β−D−リボフラノース誘導体又はその光学異性体の製造方法 | |
JP2004307407A (ja) | N6−アシル化デオキシアデノシン誘導体の加水分解法 | |
JPH09110893A (ja) | 3’−アミノ−3’−デオキシヌクレオシドの製造方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): BW GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
DPEN | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed from 20040101) | ||
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2005508024 Country of ref document: JP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2513545 Country of ref document: CA Ref document number: 11181985 Country of ref document: US |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2004700532 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 2004700532 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 11181985 Country of ref document: US |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 2004700532 Country of ref document: EP |